Apellis Pharmaceuticals/$APLS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Ticker
$APLS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
708
ISIN
US03753U1060
Website
APLS Metrics
BasicAdvanced
$2.2B
-
-$1.80
0.72
-
Price and volume
Market cap
$2.2B
Beta
0.72
52-week high
$42.47
52-week low
$16.10
Average daily volume
2.2M
Financial strength
Current ratio
4.08
Quick ratio
3.401
Long term debt to equity
281.707
Total debt to equity
285.936
Interest coverage (TTM)
-4.19%
Profitability
EBITDA (TTM)
-184.418
Gross margin (TTM)
40.56%
Net profit margin (TTM)
-28.83%
Operating margin (TTM)
-24.00%
Effective tax rate (TTM)
-0.60%
Revenue per employee (TTM)
$1,100,000
Management effectiveness
Return on assets (TTM)
-14.20%
Return on equity (TTM)
-103.82%
Valuation
Price to revenue (TTM)
2.868
Price to book
13.67
Price to tangible book (TTM)
13.67
Price to free cash flow (TTM)
-264.576
Free cash flow yield (TTM)
-0.38%
Free cash flow per share (TTM)
-6.75%
Growth
Revenue change (TTM)
48.04%
Earnings per share change (TTM)
-47.94%
3-year revenue growth (CAGR)
112.42%
3-year earnings per share growth (CAGR)
-38.89%
10-year earnings per share growth (CAGR)
-3.31%
What the Analysts think about APLS
Analyst ratings (Buy, Hold, Sell) for Apellis Pharmaceuticals stock.
Bulls say / Bears say
Apellis Pharmaceuticals reported a 97% increase in revenue in 2024, reaching $781.37 million, indicating strong sales growth. (stockanalysis.com)
Analysts have a consensus 'Buy' rating on APLS stock, with a 12-month price target of $39.06, suggesting potential upside of 125.78%. (stockanalysis.com)
The company's drug Syfovre achieved U.S. net product revenue of $611 million in 2024, demonstrating significant market adoption. (seekingalpha.com)
Apellis Pharmaceuticals' stock value was halved after reports of severe inflammation in some patients following treatment with its eye drug. (bloomberg.com)
The European Medicines Agency confirmed its negative opinion on the marketing authorization application of intravitreal pegcetacoplan for treating geographic atrophy, limiting the drug's market potential in Europe. (benzinga.com)
Citron Research issued a short call on Apellis Pharmaceuticals, expressing concerns that the FDA might issue a warning label for Syfovre after a more thorough review. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
APLS Financial Performance
Revenues and expenses
APLS Earnings Performance
Company profitability
APLS News
AllArticlesVideos
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
GlobeNewsWire·2 days ago
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
GlobeNewsWire·4 weeks ago
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Apellis Pharmaceuticals stock?
Apellis Pharmaceuticals (APLS) has a market cap of $2.2B as of July 03, 2025.
What is the P/E ratio for Apellis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Apellis Pharmaceuticals (APLS) stock is 0 as of July 03, 2025.
Does Apellis Pharmaceuticals stock pay dividends?
No, Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders as of July 03, 2025.
When is the next Apellis Pharmaceuticals dividend payment date?
Apellis Pharmaceuticals (APLS) stock does not pay dividends to its shareholders.
What is the beta indicator for Apellis Pharmaceuticals?
Apellis Pharmaceuticals (APLS) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.